Editorial: Repurposed Drugs as Immune-Modulators to Combat Infectious Diseases.

Mishra, Bibhuti B; Essafi, Makram; Singh, Ramandeep; Gupta, Shashank; Parihar, Suraj P

Mishra, Bibhuti B; Essafi, Makram; Singh, Ramandeep; Gupta, Shashank; Parihar, Suraj P.

Mishra BB; Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY, United States.
Essafi M; Laboratory of Transmission, Control and Immunobiology of Infection (LTCII), Pasteur Institute of Tunis, Tunis, Tunisia.
Singh R; Translational Health Science and Technology Institute (THSTI), Faridabad, India.
Gupta S; Division of Intramural Research, National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
Parihar SP; Wellcome Centre for Infectious Disease Research in Africa (CIDRI-Africa) and Institute of Infectious Diseases and Molecular Medicine (IDM), University of Cape Town, Cape Town, South Africa.

Front Immunol ; 13: 848373, 2022.

Article in English | MEDLINE | ID: covidwho-1765668

Subject(s)

COVID-19 Drug Treatment; Drug Repositioning; Immunologic Factors/therapeutic use; Tuberculosis/drug therapy; COVID-19/immunology; Humans; Immunomodulation/drug effects; Tuberculosis/immunology

Keywords

adjunctive therapies; immunomodulation; infectious disease; repurpose approach; vaccine

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Tuberculosis / Drug Repositioning / COVID-19 Drug Treatment / Immunologic Factors Limits: Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.848373

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google